Navigation Links
Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Children's Hospital at Stanford
Date:3/3/2008

cts males and females of all ages, but the most severe forms are frequently detected in childhood. PI often can present in the form of common illnesses such as sinus infections, pneumonia, ear infections, and bronchitis. For this reason, families and doctors are often unaware that the troubling conditions that they are dealing with are actually rooted in a defect in the immune system, and may treat the symptoms rather than addressing the underlying cause. Failure to diagnose and treat PI can lead to serious chronic illness, permanent organ damage, or even death.

"The JMF's unwavering dedication to the early diagnosis and treatment of PI is evident through its many very successful endeavors, the most recent being the expansion of diagnostic services and outreach at Lucile Packard Children's Hospital," said Larry Stern, chairman and CEO of Talecris Biotherapeutics. "Talecris is proud to collaborate with JMF and Packard -- an example of our ongoing commitment to improve the lives of so many patients with PI."

Talecris and the JMF are long-standing partners in the effort to raise awareness and increase diagnosis of PI globally. In addition to establishing diagnostic centers around the world, Talecris and the JMF have collaborated on programs to raise PI awareness in the U.S. and Europe.

About Jeffrey Modell Foundation

The Jeffrey Modell Foundation (JMF) was established in 1987 by Vicki and Fred Modell in memory of their son, Jeffrey, who died at the age of 15 of a PI disease. The Foundation is dedicated to early and precise diagnosis, meaningful treatments, and ultimately cures of PI. Today there are 37 Jeffrey Modell Research and Diagnostic Centers and more than 200 Referral Centers worldwide. The Jeffrey Modell Immunology Center at Harvard Medical School was dedicated in November 2007, and serves as a unique graduate facility for the study of immunology. More information about PI can be found at

SOURCE Talecris Biotherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Nastech Pharmaceutical Company Announces the Jeffrey Wenig Memorial Award for Outstanding Achievement in Drug Delivery
2. Neuromed Appoints Jeffrey Arcara and Gene Wright to Senior Management Team
3. James Marsden and Ashley & Jeffrey McDermott to Receive Honors at the Tourette Syndrome Association 2008 Champion of Children Awards Dinner
4. National Patient Safety Foundation Partners with Vocera Communications
5. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
6. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
7. AIDS Healthcare Foundation Applauds City Commissioners Support of Diversity, Urges Call for Mayors Resignation
8. National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour
9. Judge Rules That Florida Disease Management Program Serving 8,000 HIV/AIDS Patients Should Be Re-bid, Says AIDS Healthcare Foundation
10. The Tug McGraw Foundation Announces 2007 Fundraising Gala
11. The Arthur M. Blank Family Foundation Pushes for Pre-K Expansion in Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Operation Rescue Launches Opposition to Gov. Sebelius' Confirmation as HHS Secretary 2Health News:Operation Rescue Launches Opposition to Gov. Sebelius' Confirmation as HHS Secretary 3Health News:Latinos Manage Diabetes With Help From the Community 2Health News:Latinos Manage Diabetes With Help From the Community 3Health News:AIDS care physicians make recommendations to Obama 2Health News:Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members 2Health News:Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members 3Health News:Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members 4Health News:Three Healthcare GPOs to Offer Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) to Their Members 5Health News:New Jersey to Launch New Statewide Effort to Promote Childhood Obesity Prevention 2Health News:New Jersey to Launch New Statewide Effort to Promote Childhood Obesity Prevention 3Health News:New Jersey to Launch New Statewide Effort to Promote Childhood Obesity Prevention 4Health News:Kathleen Sebelius Ready to Lead Healthcare Reform in 2009 2
Breaking Medicine Technology:ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3Exponent Reports Second Quarter 2009 Results 52462 1Exponent Reports Second Quarter 2009 Results 52462 2Exponent Reports Second Quarter 2009 Results 52462 3Exponent Reports Second Quarter 2009 Results 52462 4Exponent Reports Second Quarter 2009 Results 52462 5Exponent Reports Second Quarter 2009 Results 52462 6Exponent Reports Second Quarter 2009 Results 52462 7Exponent Reports Second Quarter 2009 Results 52462 8Exponent Reports Second Quarter 2009 Results 52462 9Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 1Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 2Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 3Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 4Herley Industries Inc Board of Directors Concludes Strategic Alternatives Review To Discuss Conclusions with Investors at a July 22 2009 Conference 52460 5Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 1Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 2Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 3Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 4Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 5Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 6Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 7Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 8Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 9Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 10Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 11Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 12Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 13Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 14Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 15Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 16Pelosi Remarks at Press Conference Today on Health Care Reform and Medical Costs 52458 17